Seelos Therapeutics (SEEL) has released an update to notify the public and investors about the unregistered sales of equity securities.
On January 26, 2024, a company agreed to issue and sell Common Warrants for purchasing up to 3,404,256 shares of its common stock at $1.05 per share to accredited investors under a Securities Purchase Agreement. The offering closed on January 30, 2024, and was exempt from the Securities Act registration under Section 4(a)(2) and/or Rule 506 of Regulation D. The securities were acquired for investment purposes and are subject to restrictions on public resale without registration or exemption under the Securities Act.
For further insights into SEEL stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
